Surwit E A, Childers J M
Department of Obstetrics and Gynecology, Arizona Health Sciences Center, Tucson.
J Reprod Med. 1991 Jan;36(1):45-8.
Dose-intensive, multiagent chemotherapy for the treatment of high-risk gestational trophoblastic disease has evolved as the treatment of choice for these patients. High-dose methotrexate in combination with etoposide, dactinomycin, vincristine and cyclophosphamide (EMA-CO) has now been demonstrated to be superior to the traditional methotrexate, dactinomycin, cyclophosphamide chemotherapy in patients with prognostic scores of greater than or equal to 8. An attempt was made to improve upon the EMA-CO regimen by increasing the dose intensity of etoposide and adding cisplatin to the high-dose methotrexate, etoposide and dactinomycin. That regimen was used on four patients with ultra-high-risk gestational trophoblastic disease.
剂量密集型多药联合化疗已成为治疗高危妊娠滋养细胞疾病的首选方法。大剂量甲氨蝶呤联合依托泊苷、放线菌素D、长春新碱和环磷酰胺（EMA-CO）现已被证明，对于预后评分大于或等于8的患者，其疗效优于传统的甲氨蝶呤、放线菌素D、环磷酰胺化疗。有人尝试通过提高依托泊苷的剂量强度，并在大剂量甲氨蝶呤、依托泊苷和放线菌素D方案中加入顺铂来改进EMA-CO方案。该方案用于治疗4例超高危妊娠滋养细胞疾病患者。
